Neurolite takes bite out of Ceretec sales
Sales of Amersham International's Ceretec brain imaging agentdropped 11% last year due to competition from Du Pont's Neuroliteproduct, which received Food and Drug Administration approvallast year (SCAN 12/14/94). Ceretec recorded sales of 23.6 millionin
Sales of Amersham International's Ceretec brain imaging agentdropped 11% last year due to competition from Du Pont's Neuroliteproduct, which received Food and Drug Administration approvallast year (SCAN 12/14/94). Ceretec recorded sales of 23.6 millionin the company's 1995 fiscal year (end-March), or about $38 millionat current exchange rates, according to Amersham's 1995 annualreport.
Amersham, of Buckinghamshire, England, has responded to Neurolite'schallenge by differentiating its product from the Du Pont agent.Amersham is now offering a new stabilized version of Ceretec inNorth America and is also marketing the agent for white bloodcell labeling applications.
On the positive side, sales shot up 43% for Amersham's Metastronagent for palliation of bone cancer pain. Metastron had globalsales of £20.6 million, or $33 million, in the 1995 fiscalyear. Sales have grown much more quickly in Europe than in NorthAmerica, however.
Amersham's Myoview technetium-based heart imaging agent waslaunched in Japan and most European markets in the 1995 fiscalyear and sales for the period totaled £5 million, or $8 million.Amersham is still awaiting FDA approval of the product in theU.S.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Contrast-Enhanced Mammography Study Reveals 24 Percent Lower Sensitivity with Moderate/Marked BPE
April 30th 2025In comparison to minimal or mild background parenchymal enhancement on contrast-enhanced mammography (CEM), researchers found that moderate or marked BPE was associated with a 12 percent lower AUC for breast cancer detection.
Study Examines CT-Based AI Detection of Incidental Abdominal Aortic Aneurysms
April 29th 2025The AI software Viz AAA offered a sensitivity of 87.5 percent in detecting abdominal aortic aneurysms on contrast-enhanced CT, according to new retrospective research presented at the American Roentgen Ray Society (ARRS) conference.
